CASES Insights Into HER2 Breast Cancer Southeast
Perspectives from community oncologists from the southwest region of the US on current treatment practices regarding HER2+ metastatic breast cancer, and attitudes toward recently introduced and upcoming agents
Southeast – May 16, 2020
Faculty Chair
Sara Hurvitz, MD
David Geffen School of Medicine at UCLA, CA, US
REPORT SNAPSHOT
- A roundtable discussion, moderated by an Axess Oncology Network physician, focusing on treatment of HER2+ breast cancer was held on May 16, 2020, in a virtual setting
- Disease state and data presentations were developed in conjunction with Sara Hurvitz, MD, a medical expert from David Geffen School of Medicine at UCLA
- Insights on the following breast cancer therapies were obtained
- Trastuzumab (and biosimilars), lapatinib, pertuzumab, T-DM1, neratinib, tucatinib, trastuzumab deruxtecan, AIs, chemotherapies
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- A moderated virtual roundtable discussion focusing on treatment of metastatic breast cancer was held on May 16, 2020
- The group of advisors comprised 13 community oncologists from the southwest region of the US
- Data collection was accomplished through use of audience response system questioning and moderated discussion
